Focus: Sagimet Biosciences is a pre-revenue biotech focused on fatty acid synthase (FAS) inhibitors targeting metabolic diseases, oncology, and infectious diseases. The company operates as a small, private clinical-stage organization based in San Mateo, CA.
Profile data last refreshed 3h ago · AI intelligence enriched 2mo ago
Stable — net -2 jobs in 30d
1 added, 3 removed. Backfill posture.
Sagimet offers early-stage upside and scientific novelty but lacks the financial transparency, hiring scale, and publication track record needed to assess sustainability and career stability.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Sagimet Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Sagimet Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Analysts Offer Insights on Healthcare Companies: Radnet (RDNT) and MBX Biosciences, Inc. (MBX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Radnet (RDNT) and MBX Biosciences, Inc. (MBX) The Globe and Mail
Targeting the Source: Sagimet's Novel Drug Aims to Revolutionize Acne Treatment - BriefGlance
Targeting the Source: Sagimet's Novel Drug Aims to Revolutionize Acne Treatment BriefGlance
Timothy P. Walbert Joins Patient Square Capital as a Senior Advisor - pharmiweb.com
Timothy P. Walbert Joins Patient Square Capital as a Senior Advisor pharmiweb.com
Sagimet prices $175M stock offering to fund acne drug trials - Investing.com UK
Sagimet prices $175M stock offering to fund acne drug trials Investing.com UK
Sagimet Stock Surges as $175 Million Raise Sharpens Acne Drug Push - TechStock²
Sagimet Stock Surges as $175 Million Raise Sharpens Acne Drug Push TechStock²
Sagimet Biosciences Stock Soars After Positive Data For Experimental Drug In Acne Study - MSN
Sagimet Biosciences Stock Soars After Positive Data For Experimental Drug In Acne Study MSN
Showing 6 of 10 news items
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles